U.S. Markets open in 8 hrs 8 mins

Fate Therapeutics, Inc. (FATE)


NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
3.17-0.05 (-1.55%)
At close: 4:00PM EDT
People also watch
GNCACNATEVOKAKBAHTBX

Fate Therapeutics, Inc.

3535 General Atomics Court
Suite 200
San Diego, CA 92121
United States
858-875-1800
http://www.fatetherapeutics.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees66

Key Executives

NameTitlePayExercisedAge
Mr. J. Scott WolchkoFounder, Chief Exec. Officer, Pres and Director563.12kN/A47
Dr. Daniel D. Shoemaker Ph.D.Chief Scientific Officer417.35kN/A49
Dr. Stewart Abbot Ph.D.Chief Devel. Officer440.77kN/A50
Dr. Michael Rudnicki Ph.D.Co-FounderN/AN/AN/A
Ms. Cindy R. Tahl J.D.Gen. Counsel and Corp. Sec.N/AN/A44
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy that consists of adaptive memory NK cells; engineered hnCD16 induced pluripotent stem cells (iPSC)-derived natural killer cell therapy candidates for hematologic/solid tumors; and engineered chimeric antigen receptor iPSC-derived T cell therapy product candidates for hematologic/solid tumors. The company’s immuno-regulation product candidates comprise ProTmune, an investigational programmed cellular immunotherapy for use as a next-generation allogeneic hematopoietic cell transplantation cell graft; and ToleraCyte for the treatment of autoimmune and inflammatory diseases; engineered iPSC-derived CD34+ cell therapy for immune disorders. Fate Therapeutics, Inc. has a research collaboration and license agreement with Memorial Sloan Kettering Cancer Center to develop off-the-shelf T-cell immunotherapies; and strategic research collaboration and license agreement with Juno Therapeutics, Inc. to identify small molecule modulators that enhance the function of T cells. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.

Corporate Governance

Fate Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.